G49N.STU Gensight Biologics SA
- Market cap
- -
- P/E
- -
- P/B
- 30.78x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is G49N.STU undervalued?
Graham numberThe Graham number of Gensight Biologics SA cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Gensight Biologics SA fundamental analysis
No fundamental analysis for Gensight Biologics SA yet.
Gensight Biologics SA stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
Gensight Biologics SA financial statements
Gensight Biologics SA annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 0.00 | 700K | 4.39M | 5.28M | 2.58M | 1.27M | 1.50M | 1.00K |
| Operating Income | -33.0M | -30.3M | -24.9M | -28.1M | -27.8M | -29.7M | -15.8M | -11.1M |
| EBITDA | -32.7M | -29.3M | -31.4M | -25.5M | -23.9M | -20.9M | -11.4M | -8.69M |
| Net Income | -33.5M | -30.7M | -34.0M | -28.6M | -27.6M | -26.2M | -14.0M | -12.0M |
| EPS | -1.35 | -0.94 | -0.83 | -0.62 | -0.60 | -0.40 | -0.11 | -0.05 |
| Balance Sheet | ||||||||
| Total Assets | 37.0M | 32.5M | 47.4M | 56.6M | 25.9M | 9.13M | 10.8M | 8.26M |
| Total Liabilities | 13.1M | 20.7M | 35.6M | 40.7M | 41.3M | 39.8M | 37.7M | 33.2M |
| Shareholders' Equity | 23.9M | 11.7M | 11.7M | 16.0M | -15.4M | -30.7M | -26.9M | -24.9M |
| Cash & Short-term Investments | 26.2M | 19.3M | 37.9M | 44.3M | 10.6M | 2.13M | 2.46M | 2.42M |
| Cash Flow | ||||||||
| Operating Cash Flow | -28.4M | -28.1M | -15.0M | -17.1M | -33.8M | -24.7M | -12.9M | -9.17M |
| Capital Expenditure | 791K | 76.0K | 6.00K | 32.0K | 252K | 10.0K | 1.00K | 4.00K |
| Free Cash Flow | -29.2M | -28.2M | -15.1M | -17.2M | -34.0M | -24.7M | -12.9M | -9.17M |
| Ratios | ||||||||
| ROE | -140.1% | -261.5% | -289.5% | -179.0% | - | - | - | - |
| ROA | -90.5% | -94.5% | -71.8% | -50.5% | -106.5% | -287.1% | -130.2% | -145.8% |
| Net Profit Margin | - | -4,387.1% | -774.1% | -542.4% | -1,069.9% | -2,069.5% | -933.4% | -1,203,600.0% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Gensight Biologics SA dividends
Gensight Biologics SA has not paid dividends in the last 8 fiscal years.
Who owns Gensight Biologics SA
Ownership data of Gensight Biologics SA is not available yet.
Gensight Biologics SA company profile
- Company name
- Gensight Biologics SA
- Ticker
- G49N.STU
- ISIN
- FR0013183985
- Exchange
- Stuttgart Exchange
- Sector
- -
- Industry
- -
- Fiscal year end
- December
- Address
- Website
- -